4 ‐bp insertion/deletion (rs3783553) polymorphism within the 3'UTR of IL1A contributes to the risk of prostate cancer in a sample of Iranian Population
In conclusion, our findings proposed an association between IL1A 4‐bp ins/del polymorphism and PCa risk. Additional studies with enlarged sample size and diverse ethnicities are required to validate our finding. This article is protected by copyright. All rights reserved
AbstractPurposeThe aims of this retrospective analysis were to compare68Ga-PSMA PET findings and low-dose CT findings (120 kV, 30 mA), and to obtain semiquantitative and quantitative68Ga-PSMA PET data in patients with prostate cancer (PC) bone metastases.MethodsIn total, 152 PET/CT scans from 140 patients were evaluated. Of these patients, 30 had previously untreated primary PC, and 110 had biochemical relapse after treatment of primary PC. All patients underwent dynamic PET/CT scanning of the pelvis and lower abdomen as well as whole-body PET/CT with68Ga-PSMA-11. The PET/CT scans were analysed qualitatively (vi...
Conclusions99mTc-maraciclatide accumulates in PCa bone metastases in keeping with increased αvβ3 integrin expression. Greater activity in metastases with lower CT density suggests that uptake is related to osteoclast activity. Changes in planar and SPECT T:M ratios after 12 weeks of treatment differed between patients with and without PD and99mTc-maraciclatide imaging may be a potential method for assessing early response.
AbstractPurposePrevious studies in prostate cancer (PCa) patients tried to correlate the onset of local recurrence (LR) with the development of distant metastases and formulated, based on theoretical and experimental data, hypotheses linking the two events. We aimed to address this issue with11C-choline positron emission tomography/computed tomography (PET/CT).MethodsThis retrospective study included 491 PCa patients previously treated with radical prostatectomy who had undergone11C-choline PET/CT owing to biochemical failure. Further inclusion criteria were availability of clinical and pathological variables for survival ...
Conclusions18F-DCFPyL dosimetry in nine patients was obtained using novel models for the lacrimal and salivary glands, two organs with potentially dose-limiting uptake for therapy and diagnosis which lacked pre-existing models.
AbstractPurpose[68Ga]Tris(hydroxypyridinone)(THP)-PSMA is a novel radiopharmaceutical for one-step kit-based radiolabelling, based on direct chelation of68Ga3+ at low concentration, room temperature and over a wide pH range, using direct elution from a68Ge/68Ga-generator. We evaluated the clinical detection rates of [68Ga]THP-PSMA PET/CT in patients with biochemically recurrent prostate cancer after prostatectomy.MethodsConsecutive patients (n=99) referred for evaluation of biochemical relapse of prostate cancer by [68Ga]THP-PSMA PET/CT were analyzed retrospectively. Patients underwent a standard whole-body PET/CT (1 h p.i...
Conclusions: Over half of multiparametric MRI-defined targets demonstrated GS heterogeneity. The addition of high GS from TB leads to risk inflation compared with using SB alone. Further research is needed on how to integrate these findings into current risk stratification models and clinical practice.
Conclusions: With a median follow-up period of 4 years, SBRT and HDR-B monotherapy provide excellent BRFS in intermediate-risk PC. Longer-term follow-up is necessary to determine the ultimate efficacy of these hypofractionated approaches, but they appear promising relative to standard fractionation outcomes.
Prostatic inflammation: a potential treatment target for male LUTS due to benign prostatic obstruction, Published online: 24 April 2018; doi:10.1038/s41391-018-0039-8Prostatic inflammation: a potential treatment target for male LUTS due to benign prostatic obstruction
Reply to “Phase II prospective randomized trial of weight loss prior to radical prostatectomy”Reply to “Phase II prospective randomized trial of weight loss prior to radical prostatectomy”, Published online: 24 April 2018; doi:10.1038/s41391-018-0038-9Reply to “Phase II prospective randomized trial of weight loss prior to radical prostatectomy”
Men and women who receive a false-positive breast or prostate cancer screening are likely to obtain future recommended cancer screenings, a new study says.